These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15718335)

  • 1. Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
    Shamash J; Powles T; Wilson P; Ansell W; Oliver T
    J Clin Oncol; 2005 Feb; 23(6):1323-5. PubMed ID: 15718335
    [No Abstract]   [Full Text] [Related]  

  • 2. IPM chemotherapy in cytokine refractory renal cell cancer.
    Shamash J; Steele JP; Wilson P; Nystrom M; Ansell W; Oliver RT
    Br J Cancer; 2003 May; 88(10):1516-21. PubMed ID: 12771915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of small cell carcinoma of the kidney.
    Miyake M; Fujimoto K; Tanaka M; Matsushita C; Tanaka N; Hirao Y
    Hinyokika Kiyo; 2007 Apr; 53(4):235-40. PubMed ID: 17515073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal metastasis after curative resection of an epidermoid carcinoma of the esophagus].
    Nahon P; Artru P; Tournigand C; Louvet C; Krulik M; De Gramont A
    Gastroenterol Clin Biol; 2003 May; 27(5):555-6. PubMed ID: 12843922
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical study of UFT in far-advanced renal cell carcinoma].
    Matsuyama H; Yamamoto N; Sakatoku J; Hara Y; Sacho T; Yasui H; Ichikawa T; Koshido Y; Hayasida S; Nagata K
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):527-30. PubMed ID: 3126711
    [No Abstract]   [Full Text] [Related]  

  • 7. [Irinotecan (CPT-11) therapy for advanced gastric cancer].
    Sakata Y
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():386-92. PubMed ID: 11424411
    [No Abstract]   [Full Text] [Related]  

  • 8. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer].
    Terauchi F
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():175-8. PubMed ID: 15535228
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy for advanced renal-cell carcinoma: 1983-1993.
    Yagoda A; Abi-Rached B; Petrylak D
    Semin Oncol; 1995 Feb; 22(1):42-60. PubMed ID: 7855619
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical study on the effects of chemotherapy as treatment of renal cell carcinoma].
    Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):43-9. PubMed ID: 3379331
    [No Abstract]   [Full Text] [Related]  

  • 11. Temsirolimus for advanced renal-cell carcinoma.
    Ferretti G
    N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs].
    Okumura S; Nishimura T; Yoshida K; Ohhara M; Hasegawa J; Hirasawa S; Hara M; Kawamura N; Kanamori S; Akimoto M
    Hinyokika Kiyo; 1984 Sep; 30(9):1167-71. PubMed ID: 6084420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer.
    Gutman M; Abu-Abid S; Sorkine P; Inbar M; Lev D; Chen Z; Oron D; Chaitchik S; Klausner JM
    Cancer; 1996 Sep; 78(5):1125-30. PubMed ID: 8780553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
    Fennell DA; Steele JP; Shamash J; Slater SE; Sheaff MT; Wells P; Rudd RM; Stebbing J
    Int J Cancer; 2007 Dec; 121(11):2575-7. PubMed ID: 17680556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab and everolimus in renal cancer: a rational way forward.
    Stadler WM; Phillips G; George DJ; Halabi S; Small E
    J Clin Oncol; 2010 Nov; 28(33):e692-3; author reply e694. PubMed ID: 20940194
    [No Abstract]   [Full Text] [Related]  

  • 17. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
    Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
    J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.
    Zhang T; George DJ
    Clin Adv Hematol Oncol; 2020 Apr; 18(4):204-207. PubMed ID: 32628648
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer.
    Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T
    Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?
    Swanson DA
    Semin Urol; 1993 Feb; 11(1):35-40. PubMed ID: 7682003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.